Background
==========

Cancer of the prostate is the most frequently diagnosed cancer in men, accounting for 27% of new cancer cases in the United States (USA) in 2014. In the same year, 10% of the total cancer deaths in men were due to prostate cancer, the second leading cause of cancer death in this population \[[@b1-medscimonit-21-1895]\]. Although the cause of prostate cancer remains unknown, its incidence has been associated with age, ethnicity, family history, physical activity, body mass index, diet, region, and sexually transmitted infections \[[@b2-medscimonit-21-1895],[@b3-medscimonit-21-1895]\]. The seriousness of this disease warrants a more definitive investigation of its association with a history of sexually transmitted diseases.

Gonorrhea is a major public health concern worldwide. Caused by the bacterium *Neisseria gonorrhoeae*, in the year 2008 the World Health Organization estimated that there were 106 million infected adults globally, making it the most prevalent sexually transmitted bacterial infection \[[@b4-medscimonit-21-1895]\]. Several epidemiologic studies have investigated an association between gonorrhea infection and incidence of prostate cancer, but results have been inconsistent. According to a meta-analysis published by Dennis et al. \[[@b5-medscimonit-21-1895]\] in 2002, men with a history of gonorrhea were at elevated risk of prostate cancer (pooled relative risk ratio \[RR\] 1.36, 95% confidence interval \[CI\] 1.15--1.61). A meta-analysis reported by Taylor et al. \[[@b6-medscimonit-21-1895]\] in 2005 also indicated that gonorrhea was associated with increased prostate cancer risk (odds ratio \[OR\] 1.39, 95% CI 1.05--1.83). However, both of these studies were based predominantly on case-control data for white men. Studies that include African American subjects, serologic measures, and prospective data are lacking. More recently, 2 large, prospective, cohort studies \[[@b7-medscimonit-21-1895],[@b8-medscimonit-21-1895]\] and 2 case-control studies \[[@b9-medscimonit-21-1895],[@b10-medscimonit-21-1895]\] failed to confirm an association between a history of gonorrhea and prostate cancer. However, some factors were not considered in their analyses that might limit the evaluation of prostate cancer risk. These include adjustments for confounders, study design, study region, ethnicity, the method of gonorrhea exposure assessment, study quality, and the introduction of PSA screening.

Herein we provide an updated review and meta-analysis of the association between a history of gonorrhea and incidence of prostate cancer, conducting subgroup analyses based on the factors aforementioned.

Material and Methods
====================

Literature search
-----------------

We performed a systematic search of PubMed, EMBASE, and Cochrane Library databases, for all papers published up to June 2014. The following search terms were used: (gonorrhea OR *Neisseria gonorrhoeae* OR sexually transmitted diseases OR sexually transmitted infections OR venereal disease) AND (prostate cancer OR prostatic neoplasms OR prostatic cancer OR prostate neoplasms). We also searched the reference lists of all the retrieved articles to identify any other potentially relevant articles.

Study selection
---------------

To be included in this meta-analysis, the papers had to report a case-control or cohort study; evaluate the association between gonorrhea and the incidence of prostate cancer; provide relative risk ratios, ORs, and 95% CIs, or sufficient information to calculate these; and be published in English. If multiple publications from the same study population were available, only the one with the largest sample size was included.

Studies were excluded if they did not conform to the inclusion criteria above, or contained duplicate data, or were based on incomplete raw data or irrelevant data. No case reports, letters, reviews, editorials, or correspondence articles were considered.

Data extraction and quality score assessment
--------------------------------------------

Two investigators (Wen-Qing Lian and Fei Luo) independently reviewed and extracted information from all eligible publications, in accordance with the inclusion and exclusion criteria listed above. Disagreement was resolved by discussion between the 2 authors until a consensus was reached. If a consensus could not be reached, a third author (Xian-Lu Song) was consulted and a final decision was determined by majority opinion.

Data extracted from the publications included the first author, year of publication, country in which the study was performed, study design, study period, sample size, ages and ethnicities of the subjects, exposure assessment, and the confounders adjusted for. The subjects' ethnicities were categorized as white, African American, Asian, other, or mixed (a population with individuals of different ethnicities). For studies conducted in the USA, "blacks" were considered African Americans. When the paper did not specify the ethnicity of the study population, the most probable ethnicity was recorded, based on the predominant ethnic group in the study country.

The methodological quality of each eligible study was independently assessed by 2 reviewers (Wen-Qing Lian and Fei Luo) based on the Newcastle-Ottawa scale \[[@b11-medscimonit-21-1895]\], in which the total score (in stars) can range from 0 to 9. A third party (Xian-Lu Song) was involved if a consensus could not be reached. A study was considered to be of high quality if the Newcastle-Ottawa Scale score was ≥7 stars; studies given 5--6 stars were judged to be of moderate quality.

Statistical analysis
--------------------

Due to the low incidence of prostate cancer, the relative risk ratio can be mathematically approximated by the OR \[[@b12-medscimonit-21-1895]\]. In the present study, the OR and its 95% CI was used to assess the association between gonorrhea and the risk of prostate cancer. In some studies, risk estimates were stratified according to ethnic categories, and risk to the total group was not reported. For these studies, the study-specific effect size in the overall analysis was recalculated using the inverse-variance method, by pooling the risk estimates of the various ethnic categories \[[@b13-medscimonit-21-1895]\].

The statistical heterogeneity among the studies was evaluated using Cochrane's *Q* test and the *I*^2^ statistic. Regarding the former (*Q*), heterogeneity was considered to exist for *P*\<0.1. For *P*\>0.1 and *I*^2^\<50%, the included studies were identified as having acceptable heterogeneity, and the fixed-effects model was used. Otherwise, the random-effects model was used \[[@b14-medscimonit-21-1895],[@b15-medscimonit-21-1895]\].

To explore the sources of heterogeneity across studies, subgroup analyses were conducted according to study design (e.g., case-control *vs.* cohort study and population-based *vs.* hospital-based case-control study), geographic region (e.g., North America *vs.* Europe *vs.* Asia), adjustment of confounders (e.g., crude *vs.* adjusted), ethnicity (e.g., white *vs.* African American), exposure assessment (e.g., self-reported *vs.* medical record *vs.* serum antibody), and study quality (e.g., high *vs.* moderate). To determine whether estimates were influenced by the introduction of prostate-specific antigen (PSA) screening, we performed another subgroup analysis (i.e., pre-PSA *vs.* PSA-era screening) using 1994 as the cutoff \[[@b16-medscimonit-21-1895]\].

For studies that spanned numerous years, we considered the middle year as the determining date. Sensitivity analyses were performed to assess the stability of the results. The influence of individual studies was evaluated by estimating the pooled ORs after omission of each study in turn. Potential publication bias was assessed by visual inspection of Begg's funnel plots, in which the log relative risk ratios were plotted against their standard errors. We also performed Begg's and Egger's tests to assess the presence of publication bias \[[@b17-medscimonit-21-1895],[@b18-medscimonit-21-1895]\]. If the *P*-value for the Egger's test was \<0.05, we assumed that there was publication bias. All of the statistical analyses were performed with STATA statistical software (version 12.0; College Station, TX), using 2-sided *P*-values.

Results
=======

Literature search
-----------------

Initially, we retrieved 605 articles from the PubMed, EMBASE, and Cochrane Library databases that were relevant to the search terms ([Figure 1](#f1-medscimonit-21-1895){ref-type="fig"}). Of these, 110 were removed as duplicates, which left 495. By screening the titles and abstracts, 457 articles were excluded because they were reviews, editorials, or otherwise not relevant to our meta-analysis. Through full-text review of the remaining 38 articles, 5 more were found by reviewing the reference lists, while 22 were excluded because the data were incomplete or irrelevant. Finally, 21 studies \[[@b7-medscimonit-21-1895]--[@b10-medscimonit-21-1895],[@b19-medscimonit-21-1895]--[@b35-medscimonit-21-1895]\] were included for meta-analysis.

Study characteristics
---------------------

Of the 22 included studies, 19 were case-control studies \[[@b9-medscimonit-21-1895],[@b10-medscimonit-21-1895],[@b19-medscimonit-21-1895]--[@b35-medscimonit-21-1895]\] and 2 were cohort studies \[[@b7-medscimonit-21-1895],[@b8-medscimonit-21-1895]\]; all were published between 1975 and 2011 ([Table 1](#t1-medscimonit-21-1895){ref-type="table"}). Fourteen were conducted in North America \[[@b7-medscimonit-21-1895]--[@b9-medscimonit-21-1895],[@b19-medscimonit-21-1895]--[@b21-medscimonit-21-1895],[@b23-medscimonit-21-1895],[@b24-medscimonit-21-1895],[@b27-medscimonit-21-1895],[@b30-medscimonit-21-1895]--[@b33-medscimonit-21-1895],[@b35-medscimonit-21-1895]\], 5 in Europe \[[@b10-medscimonit-21-1895],[@b26-medscimonit-21-1895],[@b28-medscimonit-21-1895],[@b29-medscimonit-21-1895],[@b34-medscimonit-21-1895]\], and 2 in Asia \[[@b22-medscimonit-21-1895],[@b25-medscimonit-21-1895]\]. The sample size per study ranged from 104 to 68 675, with a total of 118 765 participants and 9965 incident cases.

Most of these studies adjudged exposure or history of gonorrhea through self-report by the participants, while 2 used medical records \[[@b21-medscimonit-21-1895],[@b27-medscimonit-21-1895]\] and 1 used serology for *Neisseria gonorrhoeae* antibodies \[[@b10-medscimonit-21-1895]\]. The quality score of studies ranged from 5 stars to 9 stars according to the 9-star Newcastle-Ottawa Scale ([Supplementary Table 1](#s1-medscimonit-21-1895){ref-type="supplementary-material"}).

Meta-analysis results
---------------------

Based on the combined results of the 21 studies, gonorrhea was significantly associated with increased risk of prostate cancer (OR 1.31, 95% CI 1.14--1.52) under the random-effects model (heterogeneity *I*^2^=38.2%, *P*=0.039; [Figure 2](#f2-medscimonit-21-1895){ref-type="fig"}). The pooled OR did not substantially change even after adjustments for confounders, study quality, or the introduction of PSA screening ([Table 2](#t2-medscimonit-21-1895){ref-type="table"}).

We also performed subgroup analyses based on study design, study region, ethnicity, and the method of gonorrhea exposure assessment ([Table 2](#t2-medscimonit-21-1895){ref-type="table"}). In the subgroup analysis based on study design, we found a significantly increased risk of prostate cancer in the case-control studies (OR 1.41, 95% CI 1.24--1.61), especially in those that were population-based (OR 1.38, 95% CI 1.19--1.61). However, the results from the cohort studies were nil (OR 1.07, 95% CI 0.95--1.21).

Regarding geographic area, there was a significant association between gonorrhea and prostate cancer risk in studies conducted in North America (OR 1.33, 95% CI 1.13--1.57), but no significant association was found in studies conducted in Europe (OR 1.18, 95% CI 0.78--1.78) or Asia (OR 1.44, 95% CI 0.84--2.48). The association between gonorrhea and prostate cancer was higher for African American men (OR 1.32, 95% CI 1.06--1.65) than whites (OR 1.05, 95% CI 0.90--1.21). The association was more significant in studies relying on self-reports of gonorrhea exposure (OR 1.34, 95% CI 1.15--1.57) than those that used medical records (OR 1.01, 95% CI 0.56--1.82) or serum antibodies (OR 1.07, 95% CI 0.42--2.73) to determine exposure.

Sensitivity analysis
--------------------

To assess the influence of the individual data sets on the pooled ORs, repeated meta-analyses that excluded each single study in turn were performed. The corresponding pooled ORs were not materially altered.

Publication bias
----------------

Begg's funnel plot and Egger's test were conducted to assess the publication bias of the studies. The shape of the funnel plots did not reveal any evidence of obvious asymmetry ([Figure 3](#f3-medscimonit-21-1895){ref-type="fig"}), and the results indicated no publication bias (*P*~Begg's~=0.695, *P*~Egger's~=0.054).

Discussion
==========

We performed a meta-analysis of 21 relevant studies published up to June 2014 to determine the association between a history of gonorrhea and prostate cancer, and found a significantly increased risk of prostate cancer among men with prior gonorrhea.

Our results were consistent with the meta-analyses of case-control studies conducted by Dennis et al. \[[@b5-medscimonit-21-1895]\] in 2002 and Taylor et al. \[[@b6-medscimonit-21-1895]\] in 2005. However, the present meta-analysis involved 19 case-control studies and 2 cohort studies, and while a significant increased risk of prostate cancer was found from the case-control studies, the association according to the cohort studies was nil. The discrepancy between the case-control and cohort studies might be due to the potential bias of case-control studies, including selection bias or recall bias. We also found that there was a stronger association shown in population-based case-control studies than in hospital-based case-control studies. Although both population- and hospital-based case-control studies contain biases, we consider the former more reliable because the cases and controls are more representative.

In the present study, subgroup analyses by ethnicity revealed a stronger association between a history of gonorrhea and prostate cancer among African Americans than among whites. These results suggest that ethnic or cultural differences exist in susceptibility to prostate cancer after gonorrhea exposure. However, this finding should be cautiously interpreted. Data from the Centers for Disease Control and Prevention (CDC) in the United States showed that in 2012 the gonorrhea rate among African American males (467.7 cases per 100 000 population) was 16 times the gonorrhea rate among white males (28.8 cases per 100 000 population), and the disparities were striking across all age groups and regions \[[@b36-medscimonit-21-1895]\]. Kwame Owusu-Edusei Jr. et al. \[[@b37-medscimonit-21-1895]\] also found that racial disparities in income were associated with racial disparities in gonorrhea rates. In addition, the higher gonorrhea rates might be due to the average lower rate of insurance, later diagnosis, less effective treatment, and greater incidence of relevant genetic polymorphisms in African Americans. Because rates of gonorrhea infection and rates of prostate cancer are each higher among African American men than among white men, we consider that many factors influencing these rates likely exist that are beyond the scope of this analysis, and any conclusions require further verification.

In the present meta-analysis, subgroup analysis showed that gonorrhea was significantly associated with increased incidence of prostate cancer in North America, but not in Europe or Asia. One possible explanation for this finding is that there was not sufficient published evidence representing European (5 studies) and Asian (2 studies) countries. This is possibly due to the exclusion criteria of the study, since we only included articles published in English. Other potential factors are the relatively low incidence of prostate cancer in Asians and the greater incidence in African Americans.

In this study, we found a significant association between gonorrhea and prostate cancer risk in the studies in which the history of gonorrhea was based on self-reports of the subjects, while the association was insignificant in studies that used medical records or serum antibodies. This finding may be due to the small number of studies that used medical records (2 studies) or serum antibodies (1 study).

The potential biological mechanisms that link gonorrhea and prostate cancer remain unclear. A general association between infections, infection-induced chronic inflammation, and the development of cancer is well-known \[[@b38-medscimonit-21-1895]\], and increasing evidence indicates that chronic inflammatory states contribute to prostate carcinogenesis \[[@b39-medscimonit-21-1895]\]. Gonorrhea infection by *Neisseria gonorrhoeae* has been shown to induce a chronic inflammatory environment within the prostate. Inflammatory cells are recruited after damage or an infection, and they can secrete a large number of cytokines (e.g., interleukin 6) and chemokines (e.g., interleukin 8) that promote the growth of neoplastic cells and ultimately lead to carcinogenesis within the prostate \[[@b40-medscimonit-21-1895],[@b41-medscimonit-21-1895]\]. The longer the inflammation persists, the higher the risk of cancer \[[@b42-medscimonit-21-1895]\]. Evidence from pathology also shows that proliferative inflammatory atrophy, which is often associated with chronic and, at times, acute inflammation, may be the direct precursor lesion to prostatic intraepithelial neoplasia, prostate cancer, or both \[[@b43-medscimonit-21-1895]\]. In addition, several genes have been studied for their role in prostate cancer development, and in some cases, (e.g., ribonuclease L\[RNASEL\]/ hereditary prostate cancer 1 \[HPC1\], toll-like receptor 4 \[TLR4\], macrophage scavenger receptor 1 \[MSR1\]) mutations or variants in these genes also increase an individual's susceptibility to infection \[[@b44-medscimonit-21-1895]\].

The present meta-analysis has some limitations. First, most of the included studies were case-control studies, which are susceptible to recall and selection biases. The statistical effect of these kinds of biases might be reduced somewhat by cohort studies, but we found only 2 suitable cohort studies. Second, the method for determining gonorrhea history or exposure varied across the studies. Gonorrhea history was mostly based on the self-report of the subjects and only 1 study conducted serological tests. This could distort the findings. Third, substantial heterogeneity was observed among the studies, although we were able to find the major sources of heterogeneity through subgroup analyses. Fourth, our results may also have been biased by restricting studies to those published in English, but there was no evidence of publication bias, based on either Egger's or Begg's test. Fifth, the effect of gonorrhea on prostate cancer outcomes may be different for cases of prostate cancer detected in the early stages through PSA screening than for patients who had aggressive fatalities before PSA screening was widely available. However, the pooled ORs in the pre-PSA and PSA-era subgroups were similar. Moreover, data stratified by prostate cancer aggressiveness were not available from the included studies. We also note that, although we performed a careful search for papers published up to June 2014, the 21 included studies all appeared between 1975 and 2011.

Conclusions
===========

Our analysis found a potential association between gonorrhea and increased risk of prostate cancer, especially among African American males. Because of the limited number of studies, more prospective cohort or intervention studies are warranted to confirm the findings of this meta-analysis. Such findings also warrant investigations of the underlying mechanisms that may be responsible for this association.

Supplementary materials
=======================

###### 

Quality assessment using the Newcastle-Ottawa Scale.

  **A.** Methodologic quality of case-control studies included in the meta-analysis.                                                
  ------------------------------------------------------------------------------------ ---- ---- ---- ---- ---- ---- ---- ---- ---- ---
  Baker et al., 1981                                                                   \+   \+   −    \+   \+   \+   −    \+   \+   7
  Checkoway et al., 1987                                                               \+   \+   −    \+   −    −    \+   \+   \+   6
  Hayes et al., 2000                                                                   \+   \+   \+   \+   \+   \+   −    \+   −    7
  Heshmat et al., 1975                                                                 \+   \+   \+   −    \+   −    −    \+   \+   6
  Hiatt et al., 1994                                                                   \+   \+   \+   \+   \+   \+   −    \+   \+   8
  Honda et al., 1988                                                                   \+   \+   \+   \+   \+   \+   −    \+   \+   8
  Hrbacek et al., 2011                                                                 \+   \+   −    \+   −    −    \+   \+   \+   6
  Hsieh et al., 1999                                                                   \+   \+   −    \+   −    −    −    \+   \+   5
  Huang et al., 2008                                                                   \+   \+   \+   \+   \+   \+   −    \+   \+   8
  Ilic et al., 1996                                                                    \+   \+   −    \+   \+   \+   −    \+   −    6
  La Vecchia et al., 1993                                                              \+   \+   −    \+   \+   \+   −    \+   \+   7
  Lees et al., 1985                                                                    \+   \+   −    \+   \+   −    −    \+   \+   6
  Mishina et al., 1985                                                                 \+   \+   \+   \+   \+   \+   \+   \+   −    8
  Oishi et al., 1989                                                                   −    \+   −    \+   \+   \+   −    \+   \+   6
  Patel et al., 2005                                                                   \+   \+   \+   \+   \+   \+   −    \+   −    7
  Pelucchi et al., 2006                                                                \+   \+   −    \+   \+   \+   −    \+   \+   7
  Rosenblatt et al., 2001                                                              \+   \+   \+   \+   \+   \+   −    \+   −    7
  Sanderson et al., 2004                                                               \+   \+   \+   \+   \+   \+   −    \+   −    7
  Sarma et al., 2006                                                                   \+   \+   \+   \+   \+   \+   −    \+   −    7

  **B.** Methodologic quality of cohort studies included in the meta-analysis.                                                                      
  ------------------------------------------------------------------------------ ------------------------------------------------------------- ---- ----
  Selection                                                                      Representativeness of the exposed cohort                      \+   \+
                                                                                 Selection of the unexposed cohort                             \+   \+
                                                                                 Ascertainment of exposure                                     \+   −
                                                                                 Outcome of interest was not present at start of study shown   \+   \+
  Comparability                                                                  Study controls for age/gender                                 \+   \+
                                                                                 Study controls for additional factors                         \+   \+
  Outcome                                                                        Assessment of outcome                                         \+   \+
                                                                                 Follow-up long enough for outcomes                            \+   \+
                                                                                 Adequacy of follow up                                         \+   \+
  Quality score                                                                                                                                9    8
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###### 

Characteristics of the studies included in the meta-analysis.

  Authors, year             Country     Ethnicities                                                            Design   Period       Cases/ subjects   Age, y                                                              Evidence of gonorrhea   Crude /adjusted   Quality
  ------------------------- ----------- ---------------------------------------------------------------------- -------- ------------ ----------------- ------------------------------------------------------------------- ----------------------- ----------------- ---------
  Baker et al., 1981        USA         Mixed                                                                  HCC      1977--1979   44/134            54--79                                                              Self-report             Crude             7
  Checkoway et al., 1987    USA         Mixed                                                                  HCC      1984--1985   40/104            50+                                                                 Self-report             Crude             6
  Cheng et al., 2010        USA         AA, White, other                                                       Cohort   2002--2006   1658/68675        45--49                                                              Self-report             Adjusted          8
  Hayes et al., 2000        USA         AA[\*](#tfn2-medscimonit-21-1895){ref-type="table-fn"}, White          PCC      1993--1996   981/2296          40--64                                                              Self-report             Adjusted          7
  Heshmat et al., 1975      USA         AA[\*](#tfn2-medscimonit-21-1895){ref-type="table-fn"}                 HCC      1973--1978   75/150            NR                                                                  Self-report             Crude             6
  Hiatt et al., 1994        USA         Mixed                                                                  PCC      1978--1985   238/476           \>30                                                                Medical record          Adjusted          8
  Honda et al., 1988        USA         White                                                                  PCC      1979--1982   216/432           ≤60                                                                 Self-report             Adjusted          8
  Hrbacek et al., 2011      Czech Rep   White[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            HCC      2004--2010   329/434           64/72[\*\*\*](#tfn4-medscimonit-21-1895){ref-type="table-fn"}       Serum antibody          Crude             6
  Hsieh et al., 1999        Greece      White[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            HCC      1994--1997   320/566           All                                                                 Self-report             Crude             5
  Huang et al., 2008        USA         AA[\*](#tfn2-medscimonit-21-1895){ref-type="table-fn"}, White, other   PCC      1993--2001   868/2151          55--74                                                              Self-report             Adjusted          8
  Ilic et al., 1996         Serbia      White[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            HCC      1990--1994   101/303           70.5/71.5[\*\*\*](#tfn4-medscimonit-21-1895){ref-type="table-fn"}   Self-report             Crude             6
  La Vecchia et al., 1993   Italy       White[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            HCC      1985--1990   271/956           \<80                                                                Self-report             Adjusted          7
  Lees et al., 1985         Canada      White[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            HCC      1962--1982   83/249            69.9                                                                Medical record          Crude             6
  Mishina et al., 1985      Japan       Asian[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            PCC      1976         100/200           45--89                                                              Self-report             Crude             8
  Oishi et al., 1989        Japan       Asian[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            HCC      1981--1984   100/200           70.6/70.0[\*\*\*](#tfn4-medscimonit-21-1895){ref-type="table-fn"}   Self-report             Crude             6
  Patel et al., 2005        USA         AA[\*](#tfn2-medscimonit-21-1895){ref-type="table-fn"}, White, other   PCC      1996--1998   700/1304          50--74                                                              Self-report             Adjusted          7
  Pelucchi et al., 2006     Italy       White[\*\*](#tfn3-medscimonit-21-1895){ref-type="table-fn"}            HCC      1985--1992   280/969           \<80                                                                Self-report             Adjusted          7
  Rosenblatt et al., 2001   USA         Mixed                                                                  PCC      1986--1989   753/1456          40--79                                                              Self-report             Adjusted          7
  Sanderson et al., 2004    USA         Mixed                                                                  PCC      2000--2002   416/845           65--79                                                              Self-report             Adjusted          7
  Sarma et al., 2006        USA         AA[\*](#tfn2-medscimonit-21-1895){ref-type="table-fn"}                 PCC      1996--2001   129/832           40--79                                                              Self-report             Adjusted          7
  Sutcliffe et al., 2006    USA         Mixed                                                                  Cohort   1992--2002   2263/36033        40--75                                                              Self-report             Adjusted          9

AA -- African American; HCC -- hospital-based case-control; NR -- not reported; PCC -- population-based case-control;

For studies conducted in the USA, we categorized "Blacks" as African Americans;

No information on ethnicity in the paper. The ethnicity was taken to be the predominant ethnicity of the study country;

The mean age of cases and controls.

###### 

Overall and subgroup analyses of the association between gonorrhea and the risk of prostate cancer.

  Subgroup                                                                                                                      Studies, n   Cases, n   Population, n       OR (95% CI)         Study heterogeneity           
  --------------------------------------------------------------- ------------------------------------------------------------- ------------ ---------- ------------------- ------------------- --------------------- ------- ------
  Overall                                                                                                                       21           9965       118765              1.31 (1.14--1.52)   32.38                 0.039   38.2
  Confounding adjustment                                          Crude                                                         9            1192       2340                1.65 (1.12--2.43)   15.17                 0.056   47.3
  Adjusted                                                        12                                                            8773         116425     1.17 (1.07--1.28)   12.49               0.328                 11.9    
  Study design                                                    Case-control study                                            19           6044       14057               1.41 (1.24--1.61)   22.99                 0.191   21.7
  Hospital-based                                                  10                                                            1643         4065       1.49 (0.97--2.28)   18.75               0.027                 52.0    
  Population-based                                                9                                                             4401         9992       1.38 (1.19--1.61)   3.94                0.862                 0.0     
  Cohort study                                                    2                                                             3921         104708     1.07 (0.95--1.21)   0.06                0.806                 0.0     
  Geographic region                                               North America                                                 14           8464       115137              1.33 (1.13--1.54)   26.13                 0.016   50.3
  Europe                                                          5                                                             1301         3228       1.18 (0.78--1.78)   5.60                0.231                 28.6    
  Asia                                                            2                                                             200          400        1.44 (0.84--2.48)   0.22                0.638                 0.0     
  Ethnicity                                                       White                                                         10           3884       49481               1.05 (0.90--1.21)   10.40                 0.319   13.5
  African American                                                6                                                             1403         8920       1.32 (1.06--1.65)   9.46                0.092                 47.2    
  Exposure assessment                                             Self-report                                                   18           9315       117606              1.34 (1.15--1.57)   31.15                 0.019   45.4
  Medical record                                                  2                                                             321          725        1.01 (0.56--1.82)   0.78                0.376                 0.0     
  Serum antibody                                                  1                                                             329          434        1.07 (0.42--2.73)   --                  --                    --      
  Quality of study                                                High                                                          14           8917       116759              1.19 (1.09--1.31)   24.65                 0.026   47.3
  Moderate                                                        7                                                             1048         2006       1.41 (1.04--1.92)   6.69                0.350                 10.4    
  PSA screening                                                   Pre-PSA[\*](#tfn5-medscimonit-21-1895){ref-type="table-fn"}   12           2301       5629                1.51 (1.11--2.05)   18.40                 0.073   40.2
  PSA era[\*\*](#tfn6-medscimonit-21-1895){ref-type="table-fn"}   9                                                             7664         113136     1.16 (1.05--1.27)   9.01                0.342                 11.2    

Prior to July 1994;

July 1994 or later.
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